Weekly Roundup for SEPTEMBER 21, 2018: Recent Publications in Women’s Mental Health
Data on the most recent randomized controlled trial of brexanolone, a novel treatment for postpartum depression, were released. (We will review those in greater detail next week.) Guidelines for the treatment of perimenopausal depression were also published. Ruta Nonacs, Md PhD Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, et al. Lancet Sept 2018. Intravenous administration of brexanolone for postpartum depression...
Options for treatment of bipolar disorder during pregnancy
August 23, 2018 from ObGynNews The management of bipolar disorder during pregnancy is a critical clinical situation demanding great attention to issues such as reproductive safety of psychiatric medications used by women with bipolar disorder to maintain emotional well-being, compared with the established risk of relapse if patients stopped those medications. Treatment of bipolar disorder frequently includes mainstay treatment with mood stabilizers such as sodium valproate, lithium, lamotrigine, and second-generation atypical antipsychotics. While we have...
Weekly Roundup for SEPTEMBER 14, 2018: Recent Publications in Women’s Mental Health
Psychiatric Medications and Reproductive Safety: Scientific and Clinical Perspectives Pertaining to the US FDA Pregnancy and Lactation Labeling Rule. Freeman MP, Farchione T, Yao L, Sahin L, Taylor L, Huybrechts KF, Nonacs R, Sosinsky AZ, Viguera AC, Cohen LS. J Clin Psychiatry. 2018 Jul 17;79(4). This is a summary of a meeting with the FDA to discuss the challenges surrounding the labelling of drugs used during pregnancy and lactation. Familiality of Psychiatric Disorders and Risk...
Marijuana Use More Common in Pregnant Women with Morning Sickness
A recent article published in JAMA Internal Medicine raises concerns regarding the increasing use of marijuana in pregnant women. According to data derived from two small surveys, women reported using marijuana to alleviate morning sickness, also known as nausea and vomiting in pregnancy (NVP). An epidemiologic study carried out in Hawaii, 4735 pregnant women (2009-2011) who self-reported their marijuana use during pregnancy; use of marijuana was more common among those with (3.7%) versus without (2.3%)...
Weekly Roundup for AUGUST 24, 2018: Recent Publications in Women’s Mental Health
This week, we have some data from our National Pregnancy Registry of Psychiatric Medications looking at infants exposed to quetiapine (Seroquel). Consistent with other studies we have seen recently, there appears to be no increase in risk of major malformations. There is also an interesting paper from DiFlorio and colleagues which assesses risk for postpartum relapse in women with bipolar disorder. In a review, Adamson and colleagues explore the impact of maternal anxiety during pregnancy...
New Research from the CWMH: Quetiapine (Seroquel) and Pregnancy Data from the National Registry
The newer “atypical” or second-generation antipsychotic agents are now used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders. The National Pregnancy Registry for Atypical Antipsychotics was created to evaluate the safety of atypical antipsychotic medications taken by women during pregnancy. The most recent publication from the registry focuses on quetiapine (Seroquel). Pregnant women were recruited and prospectively followed during pregnancy and the postpartum period. Eligible...